

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0107	
Drug name and formulations:	Betamethasone valerate medicated plaster (Betesil®)	
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Potent – so some concerns if used long term and on repeat
Clinical effectiveness	<i>Established licensed product</i>	Equivalent to existing topical corticosteroids
Strength of evidence		Good. Robust data on active agent.
Patient factors	<i>Published patient factors</i>	N/A
Cost effectiveness or resource impact	£	If no waste, cost saving compared to alternative however waste may be unavoidable
Place of therapy relative to available treatments	<i>1/2nd tier</i>	Only after other topical corticosteroids have failed, for small specific lesions
National guidance and priorities	<i>NICE, MTRAC</i>	SMC declined in 2010, however more studies available since then
Local health priorities	<i>CCG views</i>	Supportive
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	N/A
Prescribing data	<i>Requires 12 months primary or secondary care data</i>	To be monitored by CCGs and Trusts going forward

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	Amber Specialist Recommendation